迈得医疗1年1期亏损 2019年上市募资5.18亿元

Core Insights - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 275 million yuan, a decrease of 42.77% year-on-year, and a net loss of approximately 20 million yuan compared to a profit of nearly 100 million yuan in the previous year [1][3] - For the first quarter of 2025, the company continued to experience a decline in revenue, reporting 40 million yuan, down 45.87% year-on-year, and a net loss of about 10.8 million yuan compared to a profit of over 10 million yuan in the same period last year [1][4] - The company has proposed no cash dividends, stock bonuses, or capital increases for the 2024 profit distribution plan [1] Financial Performance Summary - 2024 Annual Report: - Revenue: 275 million yuan, down 42.77% from 480 million yuan in 2023 [3] - Net Profit: -20 million yuan, down 120.02% from 100 million yuan in 2023 [3] - Net Profit (excluding non-recurring items): -26 million yuan, down 130.15% from 87 million yuan in 2023 [3] - Operating Cash Flow: 56.6 million yuan, down 49.00% from 110.9 million yuan in 2023 [3] - 2025 Q1 Report: - Revenue: 40 million yuan, down 45.87% from 74 million yuan in Q1 2024 [4] - Net Profit: -10.8 million yuan, down 202.7% from 10.5 million yuan in Q1 2024 [4] - Net Profit (excluding non-recurring items): -14.4 million yuan, down 268.83% from 8.5 million yuan in Q1 2024 [4] - Operating Cash Flow: 29.7 million yuan, up 187.24% from 10.3 million yuan in Q1 2024 [4] Company Background - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 3, 2019, with an initial issuance of 20.9 million shares at a price of 24.79 yuan per share [4] - The total amount raised from the initial public offering was approximately 51.8 million yuan, with a net amount of about 45.7 million yuan after deducting issuance costs [5]